An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
about
Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug developmentEarly phase clinical trials to identify optimal dosing and safetyPhase I trials of antitumour agents: fundamental conceptsDesigns of drug-combination phase I trials in oncology: a systematic review of the literatureA Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanomaAn innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee.Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation Program.Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering CommitteePemetrexed disodium in ovarian cancer treatment.Adaptive designs for identifying optimal biological dose for molecularly targeted agents.Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.Research biopsies in the context of early phase oncology studies: clinical and ethical considerations.Innovative Clinical Trial Designs: Toward a 21st-Century Health Care SystemAmerican Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment.Novel therapies, high-risk pediatric research, and the prospect of benefit: learning from the ethical disagreements.Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents.Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies.Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.Early-phase clinical trials in the community: results from the national cancer institute community cancer centers program early-phase working group baseline assessment.Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer.Dietary supplementation with Bifidobacterium longum subsp. infantis (B. infantis) in healthy breastfed infants: study protocol for a randomised controlled trial.Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicitiesFrom drug discovery to biomarker-driven clinical trials in lymphomaBeyond chemotherapy: new agents for targeted treatment of lymphomaGuidelines for preclinical and early phase clinical assessment of novel radiosensitisersAdaptive designs for dual-agent phase I dose-escalation studies.Experimental Therapeutic Trial Design for Pediatric Brain Tumors.The changing landscape of phase I trials in oncology.A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
P2860
Q26783932-9F641426-9AEA-435E-A8FA-232F0A7D5E1AQ26865076-24E82E40-A986-4170-AF7A-ECBE1FC824C7Q26865346-E5F65ED1-075F-4E30-913F-33F0C694B019Q26996348-3D0E8D6A-E70C-4E22-BBBC-52573D91A103Q30300873-E2D60334-0081-401C-8F78-89A0EF52D0E4Q33417869-20A67DDA-83F1-4965-BBC7-EC15602E9892Q33732581-728E735D-0A42-4E10-AE95-5C3B9752F8FCQ33822083-C83B6CBE-C57F-4F52-9EA9-02B8ED3CF144Q34056295-B9FE734F-7FDB-4705-9718-9C19CC88A96FQ34253505-0C9AA3DD-66D4-4FE1-BF98-B5DBA1672542Q34550826-F5EDC5DC-3D47-4C3D-88D7-77C8AD65DD66Q35108007-CDDA484C-10F5-425A-BAAF-FE8CB5B58984Q35569312-402694D7-939C-4C49-A227-699A3EC0D76DQ35797280-AA338864-67EB-48A1-AE36-AE33743CCC3CQ35894574-AC34AEB5-16CD-48CC-B0EE-B72D1420AFFCQ36014074-5D353E13-2012-45C7-BE51-FE799C8F2AB7Q36021866-15C077D4-47D4-40EA-9F62-55FCB2D4FA2FQ36145455-CD6CB16E-F724-4BD8-A7CF-9D5691C2BB8EQ36284625-7A1D4823-A00C-478B-81B7-97AA9D700D16Q36507559-459624EE-BE4A-4C4C-81DD-A4B1F96768D0Q36678241-EA889ADE-6C00-413B-A761-2C954FBF8348Q37092020-D0B0E349-E1C7-4962-8FCE-F442777B24F2Q37118317-37584EDA-D825-46E3-A502-7777CAF1CDB9Q37270128-7F3B348A-3F14-47B9-A119-06E534A1EDEFQ37551148-047D9F63-C701-47EC-A01B-F34A75080D44Q37820097-FADD5A06-E19D-4331-8824-F86D026F9D52Q37902873-83BD3248-BD50-4A36-8C20-D3D3BF39554EQ38090897-08B2019D-E35C-473A-AA36-A4D17D6FE00BQ38583655-2F6FD808-359B-42C3-AEEA-DC75B85BF4BAQ38629203-0A2CBB16-4FC8-42C2-9D78-66D9403D0248Q55069897-F072317F-B4E3-4598-975F-B909B85E9284
P2860
An overview of the optimal planning, design, and conduct of phase I studies of new therapeutics.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An overview of the optimal pla ...... I studies of new therapeutics.
@en
An overview of the optimal pla ...... I studies of new therapeutics.
@nl
type
label
An overview of the optimal pla ...... I studies of new therapeutics.
@en
An overview of the optimal pla ...... I studies of new therapeutics.
@nl
prefLabel
An overview of the optimal pla ...... I studies of new therapeutics.
@en
An overview of the optimal pla ...... I studies of new therapeutics.
@nl
P2093
P1476
An overview of the optimal pla ...... I studies of new therapeutics.
@en
P2093
Lesley Seymour
Patricia M LoRusso
Scott A Boerner
P304
P356
10.1158/1078-0432.CCR-09-1993
P407
P577
2010-03-09T00:00:00Z